Immunology and inflammation

News

Sanofi plans amlitelimab dermatitis filing after new readout

Sanofi has said it will press ahead with regulatory filings for atopic dermatitis candidate amlitelimab, despite mixed data in phase 3.

News

A person putting wooden puzzle pieces together above grass

Abivax climbs on Lilly takeover speculation

Shares in Abivax were tracking up this morning as a media report in France suggested it could see a €15bn takeover offer from Eli Lilly.

News

Dr Jörn Drappa, Alumis' chief medical officer

Alumis shoots up as its Sotyktu rival aces psoriasis trials

Alumis is preparing to file its oral TYK2 inhibitor envudeucitinib as a treatment for psoriasis later this year, after two positive phase 3 trials.

News

Lab-in-a-loop specialist Relation attracts Novartis alliance

UK-based AI and multi-omics company Relation Therapeutics will seek out targets for allergic diseases on behalf of Novartis in a $1.7bn-plus alliance.

News

Amgen, AZ's Tezspire challenges Dupixent in nasal polyps

Amgen and AstraZeneca's fast-growing asthma drug Tezspire is now poised to take on rival Dupixent in chronic rhinosinusitis with nasal polyps.

News

MSD advances on a broad front with TL1A drug tulisokibart

MSD's confidence in its anti-TL1A drug tulisokibart in inflammatory diseases is made apparent by a decision to start trials in three new indications.

Sanofi plans amlitelimab dermatitis filing after new readout

Abivax climbs on Lilly takeover speculation

Alumis shoots up as its Sotyktu rival aces psoriasis trials

Lab-in-a-loop specialist Relation attracts Novartis alliance

Amgen, AZ's Tezspire challenges Dupixent in nasal polyps

MSD advances on a broad front with TL1A drug tulisokibart

FDA knocks back Pharming's bid for wider Joenja use

How to meet your physicians where they are online

Immunology and inflammation

Editor's Picks